Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Capital Leases (2016 - 2018)

Seres Therapeutics' Capital Leases history spans 4 years, with the latest figure at $6.8 million for Q4 2018.

  • For Q4 2018, Capital Leases fell 24.62% year-over-year to $6.8 million; the TTM value through Dec 2018 reached $6.8 million, down 24.62%, while the annual FY2018 figure was $6.8 million, 24.62% down from the prior year.
  • Capital Leases for Q4 2018 was $6.8 million at Seres Therapeutics, down from $7.7 million in the prior quarter.
  • Across five years, Capital Leases topped out at $10.7 million in Q3 2016 and bottomed at $586000.0 in Q4 2015.
  • The 4-year median for Capital Leases is $9.0 million (2017), against an average of $8.1 million.
  • The largest annual shift saw Capital Leases surged 1731.06% in 2016 before it dropped 24.62% in 2018.
  • A 4-year view of Capital Leases shows it stood at $586000.0 in 2015, then soared by 1731.06% to $10.7 million in 2016, then decreased by 16.23% to $9.0 million in 2017, then dropped by 24.62% to $6.8 million in 2018.
  • Per Business Quant, the three most recent readings for MCRB's Capital Leases are $6.8 million (Q4 2018), $7.7 million (Q3 2018), and $8.1 million (Q2 2018).